Literature DB >> 33692335

PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling.

Bomiao Cui1, Jiao Chen1, Min Luo1, Yiying Liu1, Hongli Chen1, Die Lü1, Liwei Wang1, Yingzhu Kang1, Yun Feng1, Libin Huang2, Ping Zhang3.   

Abstract

Oral squamous cell carcinoma (OSCC) has a high incidence of metastasis. Tumour immunotherapy targeting PD-L1 or PD-1 has been revolutionary; however, only a few patients with OSCC respond to this treatment. Therefore, it is essential to gain insights into the molecular mechanisms underlying the growth and metastasis of OSCC. In this study, we analysed the expression levels of protein kinase D3 (PKD3) and PD-L1 and their correlation with the expression of mesenchymal and epithelial markers. We found that the expression of PKD3 and PD-L1 in OSCC cells and tissues was significantly increased, which correlated positively with that of mesenchymal markers but negatively with that of epithelial markers. Silencing PKD3 significantly inhibited the growth, metastasis and invasion of OSCC cells, while its overexpression promoted these processes. Our further analyses revealed that there was positive feedback regulation between PKD3 and PD-L1, which could drive EMT of OSCC cells via the ERK/STAT1/3 pathway, thereby promoting tumour growth and metastasis. Furthermore, silencing PKD3 significantly inhibited the expression of PD-L1, and lymph node metastasis of OSCC was investigated with a mouse footpad xenograft model. Thus, our findings provide a theoretical basis for targeting PKD3 as an alternative method to block EMT for regulating PD-L1 expression and inhibiting OSCC growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33692335      PMCID: PMC7946959          DOI: 10.1038/s41368-021-00112-w

Source DB:  PubMed          Journal:  Int J Oral Sci        ISSN: 1674-2818            Impact factor:   6.344


  51 in total

1.  The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression.

Authors:  A Cano; M A Pérez-Moreno; I Rodrigo; A Locascio; M J Blanco; M G del Barrio; F Portillo; M A Nieto
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

2.  FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer.

Authors:  Kaixuan Wang; Wenxiang Ji; Yongfeng Yu; Ziming Li; Xiaomin Niu; Weiliang Xia; Shun Lu
Journal:  Oncogene       Date:  2018-06-01       Impact factor: 9.867

Review 3.  Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.

Authors:  Patcharee Ritprajak; Miyuki Azuma
Journal:  Oral Oncol       Date:  2014-12-12       Impact factor: 5.337

4.  Centchroman suppresses breast cancer metastasis by reversing epithelial-mesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling.

Authors:  Sajid Khan; Samriddhi Shukla; Sonam Sinha; Amar Deep Lakra; Himangsu K Bora; Syed Musthapa Meeran
Journal:  Int J Biochem Cell Biol       Date:  2014-11-07       Impact factor: 5.085

5.  Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells.

Authors:  Rong-Jane Chen; Yuan-Soon Ho; How-Ran Guo; Ying-Jan Wang
Journal:  Toxicol Sci       Date:  2008-04-30       Impact factor: 4.849

6.  MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia.

Authors:  Yanfen Fang; Like Zhong; Meihua Lin; Xinglu Zhou; Hui Jing; Meidan Ying; Peihua Luo; Bo Yang; Qiaojun He
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

7.  Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.

Authors:  Limo Chen; Don L Gibbons; Sangeeta Goswami; Maria Angelica Cortez; Young-Ho Ahn; Lauren A Byers; Xuejun Zhang; Xiaohui Yi; David Dwyer; Wei Lin; Lixia Diao; Jing Wang; Jonathon Roybal; Mayuri Patel; Christin Ungewiss; David Peng; Scott Antonia; Melanie Mediavilla-Varela; Gordon Robertson; Milind Suraokar; James W Welsh; Baruch Erez; Ignacio I Wistuba; Lieping Chen; Di Peng; Shanshan Wang; Stephen E Ullrich; John V Heymach; Jonathan M Kurie; F Xiao-Feng Qin
Journal:  Nat Commun       Date:  2014-10-28       Impact factor: 14.919

8.  Protein kinase D3 regulates the expression of the immunosuppressive protein, PD‑L1, through STAT1/STAT3 signaling.

Authors:  Bomiao Cui; Jiao Chen; Min Luo; Liwei Wang; Hongli Chen; Yingzhu Kang; Jingnan Wang; Xuedong Zhou; Yun Feng; Ping Zhang
Journal:  Int J Oncol       Date:  2020-02-04       Impact factor: 5.650

Review 9.  Protein Kinase D Enzymes as Regulators of EMT and Cancer Cell Invasion.

Authors:  Nisha Durand; Sahra Borges; Peter Storz
Journal:  J Clin Med       Date:  2016-02-03       Impact factor: 4.241

10.  PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.

Authors:  Sydney R Gordon; Roy L Maute; Ben W Dulken; Gregor Hutter; Benson M George; Melissa N McCracken; Rohit Gupta; Jonathan M Tsai; Rahul Sinha; Daniel Corey; Aaron M Ring; Andrew J Connolly; Irving L Weissman
Journal:  Nature       Date:  2017-05-17       Impact factor: 49.962

View more
  3 in total

1.  Receptor for activated C kinase 1 promotes cervical cancer lymph node metastasis via the glycolysis‑dependent AKT/mTOR signaling.

Authors:  Lixiu Xu; Jinqiu Li; Mikrban Tursun; Yan Hai; Hatila Tursun; Batur Mamtimin; Ayshamgul Hasim
Journal:  Int J Oncol       Date:  2022-05-26       Impact factor: 5.884

Review 2.  MAPK Signaling Pathway in Oral Squamous Cell Carcinoma: Biological Function and Targeted Therapy.

Authors:  Yuxi Cheng; Juan Chen; Yuxin Shi; Xiaodan Fang; Zhangui Tang
Journal:  Cancers (Basel)       Date:  2022-09-23       Impact factor: 6.575

3.  Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.

Authors:  Lars Hanker; Frank Köster; Karen Bräutigam; Elodie Kabore-Wolff; Ahmad Fawzi Hussain; Stephan Polack; Achim Rody
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-29       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.